503Pharma Weekly Compounding Pharmacy Roundup

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

This Week's Headlines

Breaking

Novo Nordisk and Hims & Hers Settle Lawsuit — Hims Will Sell Branded Wegovy and Ozempic, Drop Compounded GLP-1 Marketing

Novo Nordisk dropped its February patent infringement suit against Hims & Hers after the two reached a distribution agreement. Hims will now offer branded Ozempic and Wegovy (injectable and oral) at standard telehealth self-pay prices, and will stop advertising compounded GLP-1 products — limiting compounded offerings only to cases where a provider deems it clinically necessary. Novo reserves the right to refile. Hims stock surged more than 40% on the news. For 503A compounders, this is a major structural shift: the largest DTC telehealth channel for compounded GLP-1s is now pivoting to branded distribution, further narrowing the viable market for compounded semaglutide.

Reuters → Novo Nordisk strikes deal for Hims to sell Wegovy and Ozempic

Enforcement

FDA Sends 30 Warning Letters to Telehealth Companies Over Compounded GLP-1s

Agency cited misleading claims that compounded versions are identical to FDA-approved products. Novo Nordisk testing found impurities up to 86% in some compounded GLP-1 samples. This represents a systematic escalation targeting the DTC compounded GLP-1 market ahead of potential shortage resolution.

FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s

Policy

RFK Jr. Signals Delisting of 14 Peptides from FDA's Prohibited Compounding List

HHS Secretary Kennedy announced plans to remove 14 peptides — potentially including BPC-157 and MK-677 — from FDA's Category 2 bulk drug list within weeks. Timing overlaps directly with BPC-157's new IND status, creating significant enforcement ambiguity for 503A pharmacies.

Gizmodo → RFK Jr. Tells Joe Rogan He's About to Unleash 14 Banned Peptides

Lead Story

BPC-157 Enters FDA Clinical Trial Pipeline

The first FDA-registered Phase 2 trial for BPC-157 launched February 27, evaluating the pentadecapeptide for grade II hamstring injury recovery over 14 days. Co-primary endpoints: return-to-sport timing and MRI-assessed injury volume. This is the first controlled test of a Category 2 peptide's therapeutic claims.

The filing carries an IND application — and that's the enforcement problem for 503A pharmacies. Under section 503A(b)(1)(A)(i)(II), compounding a drug that is the subject of an approved IND is restricted. FDA now has a clear statutory basis to challenge routine BPC-157 compounding, independent of whether Kennedy succeeds in delisting it.

Even a successful delisting does not eliminate the IND enforcement pathway. Both regulatory tracks are now live simultaneously.

BPC 157 for Acute Hamstring Muscle Strain Repair (BPC-HAMSTR)

NEW: 503Pharma Formula Library

We just launched a formula library for compounding pharmacies — 90+ ready-to-use formulations, now live in the members area at app.503pharma.com.

Every formula is built for real compounding workflows: USP 795/797-compliant, sterile and non-sterile coverage, beyond-use dating included, and updated as guidance evolves. No starting from scratch, no hunting through scattered references.

What's inside:

• 90+ formulations across sterile and non-sterile categories

• BUD assignments aligned to USP 795/797

• Ready-to-use format — drop into your compounding records directly

• Regularly updated as FDA and USP guidance changes

The members area is free to join. Formula access is a paid feature.

Access the Formula Library

FDA Finalizes 12-Digit NDC Format — Operational Changes Required

FDA's March 5 final rule standardizes NDC to a fixed 12-digit format: 6-digit labeler code / 4-digit product code / 2-digit package code. Variable-length formats are eliminated. Pharmacy management software, label printing systems, and barcode configurations are all affected. Compliance timeline for compounded preparations has not yet been specified.

Action Items

• Contact your pharmacy software vendor immediately about their 12-digit NDC update timeline

• Confirm label printer configurations will maintain barcode scanability at the new format

• Verify whether current labeler codes map cleanly to the 6-digit segment or require new NDC block assignment

• Begin transition planning now — don't wait for FDA to publish a compounding-specific compliance date

FDA Final Rule

CompoundLearn: Training Built for Compounding Pharmacies

CompoundLearn simplifies USP compliance training so your team can stay inspection-ready without the spreadsheets and paper trails. From onboarding new staff to competency testing, CompoundLearn automates the entire training lifecycle — so you can focus on what matters most: patient safety.

• Full access to 25 training modules and 77 lessons covering critical USP 795, 797, and 800 topics

• Role-based assignments — assign and track the right training curriculum to designated persons/pharmacists-in-charge, compounders, and trainers

• Quizzes and Downloadable certificates that prove that your team knows the material

• 23+ Ready-Made Compliance Templates — Downloadable cleaning logs, sampling records, labeling checklists, and more — ready to use out of the box

• Custom Module Creation — Build pharmacy-specific training for your unique protocols and SOPs

• Team & Role Management — Assign training by role (designated person, compounder, technician) and track progress across your entire organization

[Start Now at CompoundLearn →]

Intel Brief

OMB Reviews 503A/503B Reporting Requirements

FDA's proposed data collection framework for 503A and 503B facilities entered final OMB review February 23. If approved, this formalizes federal documentation obligations on top of existing state board requirements. Watch for finalization in coming weeks.

Federal Register → Agency Information Collection Activities, Feb 23 2026

✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.